RNS Reach
AIM: FIPP
25 July 2019
Frontier IP Group Plc
("Frontier IP" or the "Group")
Portfolio news - Exscientia enters broad rare disease drug discovery collaboration with Rallybio
Frontier IP, a specialist in commercialising university intellectual property, is pleased to note the following announcement from portfolio company Exscientia ("Exscientia" or the "Company"), a world leader in artificial intelligence ("AI") drug discovery, that it has entered into a drug discovery collaboration with Rallybio.
Rallybio is a US-based drug development company aiming to transform the lives of patients with rare diseases.
Exscientia's other partnerships include collaborations with Celgene, GSK, Roche, Sanofi, GT Apeiron and Evotec. Frontier IP currently holds a 3.25 per cent stake in the Company.
Exscientia statement in full:
EXSCIENTIA ENTERS BROAD RARE DISEASE DRUG DISCOVERY COLLABORATION WITH RALLYBIO
Joint venture will initiate drug discovery programs targeting rare diseases using AI
Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered into a collaboration with Rallybio, a U.S.-based drug development company, which aims to transform lives of patients with rare diseases. The collaboration will combine Exscientia's AI drug discovery platform with Rallybio's expertise in rare disease drug development to accelerate the discovery of small molecule drug therapeutics for undisclosed rare disease indications.
It is estimated that there are between 7,000 and 8,000 rare diseases, which affect 25 to 30 million Americans and 30 to 40 million European Union citizens. These diseases pose unique challenges to the healthcare systems around the world because they require specific medical expertise and significant drug research, diagnostic and screening capabilities in order to treat these patients.
Alongside the team of world-class scientists from Rallybio, Exscientia will apply its cutting-edge, Centaur Chemist™, AI drug discovery platform to design pre-clinical drug candidates for the joint venture, RE Ventures, owned equally by Exscientia and Rallybio. The financial details of the collaboration are not disclosed.
"There is a huge potential for artificial intelligence to revolutionise and democratise rare disease drug discovery. AI can fast track, simplify and lower the price of research and we are thrilled to be partnering with Rallybio to achieve this. The future of drug discovery in rare diseases is to be able to address the need for precision engineered drugs at scale and our collaboration with Rallybio is the first step in this direction," said Andrew Hopkins, CEO of Exscientia.
"Our joint venture brings together Exscientia's industry-leading AI drug discovery capabilities with Rallybio's expertise in rare disease drug development," said Steve Uden, Chief Operating Officer of Rallybio. "We believe this collaboration will accelerate the development of life-transforming therapies for patients suffering from severe and rare disorders."
Exscientia statement ends
ENQUIRIES
Frontier IP Group Plc |
T: 020 7332 2338 |
Neil Crabb, Chief Executive Andrew Johnson, Communications & Investor Relations Company website: www.frontierip.co.uk |
M: 07464 546 025 |
Allenby Capital Limited (Nominated Adviser and Broker) |
T: 0203 328 5656 |
Nick Athanas / Nicholas Chambers (Corporate Finance) Amrit Nahal (Equity Sales) |
|
Exscientia Limited Corporate enquiries: |
|
Mark Swindells, Chief Operating Officer Company website: www.exscientia.co.uk Twitter: www.twitter.com/exscientialtd |
[email protected] |
Exscientia media enquiries: Edelman |
[email protected] |
Sesh Rahim |
+44(0) 203 047 4207 |
Camille Oster |
+44(0) 7812660934 |
NOTES FOR EDITORS
About Exscientia
Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches.
Exscientia's innovative Centaur Chemist™ platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds are automatically designed and prioritised for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development.
Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria.
As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour.
Exscientia is collaborating with several leading pharmaceutical and life sciences companies, including GSK, Sanofi and Evotec.
Exscientia has its headquarters in Oxford, UK, with offices in the UK, USA and Japan. For more information visit www.exscientia.co.uk or follow us on Twitter @exscientialtd
ABOUT FRONTIER IP
Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
ABOUT RNS REACH ANNOUNCEMENTS
This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.
